Shots:
- Interna has entered into a research collaboration with Daiichi Sankyo via its Daiichi Sankyo Research Institute Boston to evaluate its MNM technology as a delivery enhancer for targeted therapeutic modalities
- As per the deal, the companies will integrate MNM molecules with targeting approaches to enhance intracellular delivery & therapeutic performance, initially focusing on preclinical studies with potential expansion to broader research activities & additional programs; financial terms were undisclosed
- The MNM platform enables efficient intracellular delivery of diverse cargos, incl. nucleic acids & macromolecules, without traditional systems, enhancing tissue penetration & potentially improving efficacy of targeted therapies across multiple indications
Ref: PRnewswire | Image: Interna & Daiichi Sankyo | Press Release
Related News: Daiichi Sankyo and Merck Receives FDA’s Priority Review for Ifinatamab Deruxtecan (I-DXd) to Treat ES-SCLC
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
